James E. Bradner
Impact in
- Molecular Biology top 0.02%
- Protein Degradation and Inhibitors
- Genomics and Chromatin Dynamics
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Chromatin Remodeling and Cancer
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Papers in
-
- Protein Degradation and Inhibitors 97
- Histone Deacetylase Inhibitors Research 45
- Genomics and Chromatin Dynamics 37
- Chromatin Remodeling and Cancer 27
- Epigenetics and DNA Methylation 19
- Hematology 56
- Acute Myeloid Leukemia Research 23
- Multiple Myeloma Research and Treatments 21
- Co-authors
- Richard A. Young (14 shared papers)Jun Qi (70 shared papers)Charles Y. Lin (17 shared papers)Tong Ihn Lee (6 shared papers)Dennis L. Buckley (16 shared papers)Jakob Lovén (4 shared papers)Denes Hnisz (4 shared papers)Christopher R. Vakoc (7 shared papers)
- Journals
- Blood (60 papers)Nature (14 papers)Cell (13 papers)Cancer Research (12 papers)Proceedings of the National Academy of Sciences (12 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
James E. Bradner
330 papers receiving 54.3k citations
James E. Bradner's Hit Papers
Peers
Comparison fields: 5 of 151
- Molecular Biology 33.7k
- Hematology 4.1k
- Genetics 2.6k
- Cancer Research 3.1k
- Oncology 5k
Countries citing papers authored by James E. Bradner
This map shows the geographic impact of James E. Bradner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Bradner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Bradner more than expected).
Fields of papers citing papers by James E. Bradner
This network shows the impact of papers produced by James E. Bradner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Bradner. The network helps show where James E. Bradner may publish in the future.
Co-authors
The 25 scholars most cited alongside James E. Bradner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 335 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Selective inhibition of BET bromodomains Hit paper breakdown → | 2010 | 3546 |
| 2 | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Hit paper breakdown → | 2011 | 2419 |
| 3 | Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers Hit paper breakdown → | 2013 | 2353 |
| 4 | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Hit paper breakdown → | 2011 | 1587 |
| 5 | Phthalimide conjugation as a strategy for in vivo target protein degradation Hit paper breakdown → | 2015 | 1433 |
| 6 | HDAC2 negatively regulates memory formation and synaptic plasticity Hit paper breakdown → | 2009 | 1368 |
| 7 | The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins Hit paper breakdown → | 2013 | 1302 |
| 8 | Transcriptional Amplification in Tumor Cells with Elevated c-Myc Hit paper breakdown → | 2012 | 1208 |
| 9 | R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling Hit paper breakdown → | 2017 | 941 |
| 10 | Transcriptional Addiction in Cancer Hit paper breakdown → | 2017 | 913 |
| 11 | The dTAG system for immediate and target-specific protein degradation Hit paper breakdown → | 2018 | 797 |
| 12 | Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies Hit paper breakdown → | 2007 | 776 |
| 13 | YY1 Is a Structural Regulator of Enhancer-Promoter Loops Hit paper breakdown → | 2017 | 730 |
| 14 | 2005 | 673 | |
| 15 | PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib Hit paper breakdown → | 2007 | 652 |
| 16 | Direct inhibition of the NOTCH transcription factor complex Hit paper breakdown → | 2009 | 651 |
| 17 | Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma Hit paper breakdown → | 2013 | 626 |
| 18 | Chemical phylogenetics of histone deacetylases Hit paper breakdown → | 2010 | 623 |
| 19 | Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset Hit paper breakdown → | 2015 | 591 |
| 20 | Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Hit paper breakdown → | 2016 | 538 |
About James E. Bradner
James E. Bradner is a scholar working on Molecular Biology, Hematology, Genetics, Oncology and Cancer Research, having authored 335 papers that have together received 55.4k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (97 papers), Histone Deacetylase Inhibitors Research (45 papers), Genomics and Chromatin Dynamics (37 papers), Chromatin Remodeling and Cancer (27 papers), Acute Myeloid Leukemia Research (23 papers), Multiple Myeloma Research and Treatments (21 papers), Epigenetics and DNA Methylation (19 papers) and Acute Lymphoblastic Leukemia research (17 papers). The work is most often cited by research in Molecular Biology (33.7k citations), Hematology (4.1k citations), Genetics (2.6k citations), Cancer Research (3.1k citations) and Oncology (5k citations). James E. Bradner has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Richard A. Young, Jun Qi, Charles Y. Lin, Tong Ihn Lee, Dennis L. Buckley, Jakob Lovén, Denes Hnisz, Christopher R. Vakoc, Joshiawa Paulk and Georg E. Winter. Their work appears in journals such as Blood, Nature, Cell, Cancer Research and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.